Chemomab Shareholders Approve Capital Increase, Director Re-election

Chemomab Therapeutics Ltd. announced the results of its annual general shareholders meeting, which was held on May 5, 2026. Shareholders approved the re-election of Mr. Neil Cohen and Dr. Claude Nicaise as Class II directors. Key proposals also approved included the compensation policy for office holders and directors, an increase in the company's authorized share capital, and the re-appointment of Somekh Chaikin (KPMG) as the independent registered public accounting firm for the fiscal year ended December 31, 2026.